Research opportunity: Two RFPs from Wellcome Trust in support of the UN IACG

Dear All:

I have just learned that Wellcome Trust is seeking applications to address an RFP (Request for Proposal) for two pieces of work designed to support the recently created UN Interagency Coordination Group (IACG) on AMR.

  • RFP #1 is for a review of the roles, responsibilities and remit of UN organisations in relation to AMR, identifying what agencies are doing now as well as where they might further engage in order to increase engagement on AMR.
  • RFP #2 is for an assessment of the global indicator framework for Sustainable Development Goals (SDGs) and targets for the 2030 Agenda for Sustainable Development, identifying where AMR-specific and AMR-sensitive indicators could be included in the SDG targets/indicators to broaden their scope to include AMR.

This is an important but specialized project! Please forward this email to anyone who you think might be interested. Contact details and the full RFP are provided in the document at this link. The stated deadline is 15 Dec. Recognizing that this is a tight window, I’d suggest reaching out to the contact provided in the document if you have further queries.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

Further background details
During the 71st Session of the United Nations (UN) General Assembly, Member States adopted the Political Declaration of the High Level Meeting on Antimicrobial Resistance (AMR). The declaration recognised the magnitude of AMR as a global problem and called for the UN Secretary General to establish an ad hoc Interagency Coordination Group (IACG) on AMR. The IACG was established earlier this year, creating six sub-groups to review progress on AMR and support the development of recommendations to be fed back to the UN Secretary General during the 73rd session of the UN General Assembly.

The Wellcome Trust are supporting the work of sub-group five who will focus on sustainable development goal (SDG) alignment, global governance post 2019 and UN roles and responsibilities. Sub-group five has a number of areas where they wish to commission work, the outputs from which will be used to inform thinking on AMR and their recommendations back to the UN Secretary General.

The Request for Proposal (RFP) document provides full details of the first two pieces of work Wellcome Trust is seeking to commission on behalf of IACG sub-group five.

The first commission is a review of the roles, responsibilities and remit of UN organisations in relation to AMR, identifying what agencies are doing now as well as where they might further engage in order to increase engagement on AMR.

The second commission is an assessment of the global indicator framework for SDGs and targets for the 2030 Agenda for Sustainable Development, identifying where AMR specific and AMR sensitive indicators could be included in the SDG targets/indicators to broaden their scope to include AMR.

Please note these commissions have been included under the same RFP as suppliers are welcome to submit a proposal for both pieces of work to be done in parallel, however this is not essential and individual bids are also encouraged.

Upcoming meetings of interest to the AMR community:

Share

ENABLE-2 funding now includes Hit Identification & Validation

Dear All, I wrote on 25 Aug 2023 about the ENABLE-2 program and its support for hit-to-lead compound development. As a reminder, that program is focused on molecules with the potential to be direct-acting therapies for one or more of the following priority pathogens: ESBL-producing/carbapenem-resistant Enterobacteriaceae (E. coli, K. pneumoniae), P. aeruginosa, A. baumannii, methicillin-resistant S. aureus, or vancomycin-resistant E. faecium. Adding to that program, there is now an ENABLE-2

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

The (confusing!) language of AMR: ChatGPT tries to help!

Dear All (Wonkish alert! Not technical but lengthy … so settle in and enjoy the ride!): Regular readers will know of my fascination with language: e.g., this 20 Feb 2020 newsletter entitled “Language Matters: CRE vs. CPE; SDD vs. I; And MDR, XDR, PDR, UDR vs. DTR.” How about that for acronymics taken to Olympian

Scroll to Top